Cyclopharm Limited (AU:CYC)
ASX:CYC
Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.98
-AU$0.04(-1.82%)
At close: 4:00 PM EST
AU$0.98
-AU$0.04(-1.82%)
Day’s Range― - ―
52-Week RangeAU$0.52 - AU$1.29
Previous CloseN/A
Volume20.15K
Average Volume (3M)97.64K
Market Cap
AU$71.23M
Enterprise ValueAU$75.74M
Total Cash (Recent Filing)AU$6.63M
Total Debt (Recent Filing)AU$14.92M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding126,065,790
10 Day Avg. Volume155,345
30 Day Avg. Volume97,642
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside2.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$47.80M
Bulls Say, Bears Say
Bulls Say
Stable Revenue GrowthConsistent top-line expansion across multiple years signals durable commercial traction for Technegas. Steady revenue growth improves the likelihood that installed-base adoption and recurring procedure volumes can continue funding operations and scale, making recovery of margins feasible if costs are controlled.
Equity Capital BufferA tangible equity cushion provides resilience against ongoing losses and gives management time to execute restructuring or commercialization initiatives without immediate insolvency risk. This buffer reduces near-term refinancing pressure and supports funding of operating needs over several quarters.
Recurring Consumables Business ModelA consumables-driven model yields repeatable, usage-linked revenues from an installed base of generators and equipment. Over time, such recurring demand can produce steady cash flows and higher lifetime customer value, underpinning durable revenue visibility if utilization and market access remain intact.
Bears Say
Negative Gross Profit And Margin DeteriorationA negative gross profit indicates that direct costs now exceed product revenue, a structural issue that undermines any revenue growth. Without material changes to pricing, manufacturing efficiency, or product mix, sustained negative gross margins will prevent path to operating profitability and require strategic remediation.
Heavy Cash Burn And Negative Operating Cash FlowLarge, persistent negative operating and free cash flows create ongoing funding needs and force reliance on external financing or equity issuance. This undermines long-term flexibility, limits ability to invest in commercial expansion or R&D, and raises the probability of dilution or constrained operations absent a clear cash-flow recovery plan.
Rising Leverage And Balance Sheet PressureMaterial debt growth alongside declining equity elevates financial risk through higher interest obligations and potential covenant exposure. Rising leverage reduces strategic optionality, increases refinancing risk in stressed markets, and limits the firm's ability to invest in growth or absorb further operational setbacks.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.52 and its highest was AU$1.29 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$71.23M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Aug 17, 2026 which is in 57 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.086.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Undervalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 126,065,790 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (2.04% Upside)
AU$1.00 (2.04% Upside)
Blogger Sentiment
Bullish
AU:CYC Sentiment 89%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.35%
12-Months-Change
Fundamentals
Return on Equity
-54.48%
Trailing 12-Months
Asset Growth
-25.80%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector. Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments. Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.
CYC Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(2.04% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---